Yan Leyfman
Impact in
-
- Cancer Cells and Metastasis
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
-
- Cancer Genomics and Diagnostics
Papers in
- Oncology 13
- CAR-T cell therapy research 3
- COVID-19 and healthcare impacts 3
- Cancer Cells and Metastasis 2
- Cancer Immunotherapy and Biomarkers 2
-
- Lung Cancer Diagnosis and Treatment 2
- Co-authors
- Jingfang Ju (2 shared papers)Galina I. Botchkina (2 shared papers)Yuan Wang (2 shared papers)James Lee (1 shared paper)Adil Daud (1 shared paper)Laura A. Huppert (1 shared paper)Michael D. Green (1 shared paper)Luke Kim (1 shared paper)
- Journals
- Cancers (7 papers)Therapeutic Advances in Medical Oncology (2 papers)Cancer Investigation (2 papers)Molecular Therapy (1 paper)Cellular and Molecular Immunology (1 paper)
- Partner nations
- United StatesGeorgiaItaly
In The Last Decade
Yan Leyfman
24 papers receiving 335 citations
Peers
Comparison fields: 5 of 74
- Oncology 195
- Cancer Research 61
- Immunology 71
- Biotechnology 28
- Molecular Biology 117
Countries citing papers authored by Yan Leyfman
This map shows the geographic impact of Yan Leyfman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Leyfman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Leyfman more than expected).
Fields of papers citing papers by Yan Leyfman
This network shows the impact of papers produced by Yan Leyfman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Leyfman. The network helps show where Yan Leyfman may publish in the future.
Co-authors
The 25 scholars most cited alongside Yan Leyfman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. | 2009 | 88 |
| 2 | 2021 | 84 | |
| 3 | 2010 | 66 | |
| 4 | 2020 | 16 | |
| 5 | 2022 | 13 | |
| 6 | 2018 | 11 | |
| 7 | 2022 | 10 | |
| 8 | 2023 | 8 | |
| 9 | 2024 | 8 | |
| 10 | 2021 | 7 | |
| 11 | 2022 | 7 | |
| 12 | 2024 | 3 | |
| 13 | 2023 | 3 | |
| 14 | 2023 | 3 | |
| 15 | 2019 | 2 | |
| 16 | 2024 | 1 | |
| 17 | 2025 | 1 | |
| 18 | 2024 | 1 | |
| 19 | 2023 | 1 | |
| 20 | 2025 | 1 |
About Yan Leyfman
Yan Leyfman is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Infectious Diseases and Molecular Biology, having authored 25 papers that have together received 338 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (4 papers), CAR-T cell therapy research (3 papers), COVID-19 Clinical Research Studies (3 papers), Lymphoma Diagnosis and Treatment (3 papers), COVID-19 and healthcare impacts (3 papers), Cancer Cells and Metastasis (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). The work is most often cited by research in Oncology (195 citations), Cancer Research (61 citations), Immunology (71 citations), Biotechnology (28 citations) and Molecular Biology (117 citations). Yan Leyfman has collaborated with scholars based in United States, Georgia and Italy. Frequent co-authors include Jingfang Ju, Galina I. Botchkina, Yuan Wang, James Lee, Adil Daud, Laura A. Huppert, Michael D. Green, Luke Kim, Christine Chow and Antoine Dufour. Their work appears in journals such as Cancers, Therapeutic Advances in Medical Oncology, Cancer Investigation, Molecular Therapy and Cellular and Molecular Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.